Starpharma & Okamoto Industries Inc
2906
post-template-default,single,single-post,postid-2906,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-5.7,vc_responsive

Starpharma & Okamoto Industries Inc

Starpharma & Okamoto Industries Inc

Medical applications and devices are an expanding area of Australia-Japan business. The ASX-listed Starpharma’s core technology is “built around dendrimers, a type of synthetic nanoscale polymer that is highly regular in size and structure, and well-suited to pharmaceutical and medical uses.” Starpharma has announced it’s received regulatory approval in Japan for its VivaGel® condom, and has worked with Okamoto Industries Inc, the country’s largest condom manufacturer, on the product. Established in 1934, Okamoto manufactures a diverse range of industrial goods and lifestyle products, and has a consolidated group turnover of over AUD $1 billion.